HOME > Publication List English > 詳細

2021/08/19

Patient-Derived Cancer Xenograft Zebrafish Model (PDXZ) for Drug Discovery Screening and Personalized Medicine

The U.S. National Cancer Institute has been using bank-derived cell lines for drug screening for many years, but due to the lack of clinical efficacy of this 2D cell culture drug screening (<5%), it was discontinued in 2016, and patient-derived xenograft mouse model (PDXM, >80% clinical drug efficacy predictive capacity) has been rapidly developed internationally.

However, the PDXM requires severe immunodeficient mice, and it takes about one year to obtain quantitative drug efficacy test results, and many issues remain, such as cost.

We developed novel zebrafish model for patient-derived xenograft (PDXZ), and demonstrated that PDXZ has high rate and speed of engraftment in normal zebrafish when the immune system is immature, requires less than 100 patient cancer cells for transplantation, and can be quantitatively analyzed in 2 days. We report on the construction of a drug efficacy screening system that can be quantitatively analyzed within a week.